Rapport Therapeutics Inc RAPP
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-06-07 |
| Shares Out. | 47,830,000 |
| Website | rapportrx.com/ ↗ |
| Phone | 18573218020 |
| Employees | 84 |
| Revenue | $20.0M |
| Gross Profit | $20.0M |
| Net Income | -$19.9M |
| Free Cash Flow | -$80.7M |
| Total Assets | $497.6M |
| Total Liabilities | $26.1M |
| Equity | $471.5M |
About Rapport Therapeutics Inc
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Rapport Therapeutics Inc is a publicly traded company under the ticker symbol RAPP on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)